XOMA Royalty (LTS:0M26) FFO


LTS:0M26 XOMA Royalty Corp LTS:0M26
35 GF Score
Price $42.29
GF Value $18.91
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is XOMA Royalty FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0M26
35GF Score
XOMA Royalty Corp LTS:0M26
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is XOMA Royalty (LTS:0M26) Overvalued in 2026?

Based on GuruFocus' analysis, XOMA Royalty stock appears to be overvalued. The current stock price of $42.29 is trading 123.6% above its estimated GF Value™ of $18.91. GuruFocus considers XOMA Royalty to be Significantly Overvalued.

Key valuation signals for LTS:0M26:

  • FFO:
  • GF Value™: $18.91 vs. price of $42.29 (123.6% above fair value)
  • GF Score™: 35/100 with 9 warning signs

No single metric tells the full story. See the LTS:0M26 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

XOMA Royalty Business Description

Address 2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.
35GF Score

Get the complete analysis for LTS:0M26

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.29
Price
$18.91
GF Value